Neurocrine Biosciences, Inc.
553 articles with Neurocrine Biosciences, Inc.
-
Neurocrine Biosciences to Present at the Stifel 2023 CNS Days
3/21/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2023 CNS Days at 12:30 p.m. Eastern Time on Tuesday, March 28, 2023.
-
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference
3/9/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from three in vitro dissolution studies exploring the dissolution performance of INGREZZA® (valbenazine) capsule contents through soft foods or a gastrostomy (G-tube) feeding tube.
-
Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study
3/9/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that new data from RE-KINECT ™ , the largest real-world, observational, multicenter study of antipsychotic-treated patients with possible tardive dyskinesia (TD), was published in the Journal of Patient-Reported Outcomes.
-
Neurocrine Biosciences to Participate at Investor Conferences in March
3/8/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 10:45 a.m. Eastern Time on Wednesday, March 15 2023 in Miami.
-
Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting
3/3/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (TD) with INGREZZA® (valbenazine) capsules in older (≥55 years) and elderly (≥65 years) patients from two studies (KINECT™ 3-extension and KINECT™ 4).
-
Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference
2/7/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 p.m. Eastern Time on Tuesday, February 14, 2023. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.
-
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
2/6/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided financial guidance for 2023.
-
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results
1/17/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on February 6, 2023.
-
Neurocrine Biosciences and Voyager Therapeutics inked a CNS-targeted collaboration potentially worth a potential $4.4 billion.
-
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
1/9/2023
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases.
-
Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 41st Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Pacific Time on Monday Jan. 9, 2023 in San Francisco.
-
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
12/22/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for valbenazine as a treatment for chorea associated with Huntington disease (HD).
-
Neurocrine's NBI-827104 failed to meet the primary endpoint in a Phase II study for epileptic encephalopathy with continuous spike-and-wave during sleep, the company announced Tuesday.
-
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
12/6/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT™ study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS).
-
Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022
12/2/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A -related epilepsies.
-
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences - November 08, 2022
11/8/2022
Neurocrine Biosciences, Inc. announced that members of the management team will participate at the following investor conferences.
-
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
11/3/2022
Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease (HD).
-
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting
11/3/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA® (valbenazine) capsules evaluating in vitro dissolution performance of whole intact or crushed capsule contents in 40 mg and 80 mg strength.
-
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
11/1/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2022 and raised net sales guidance for INGREZZA in 2022.
-
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
10/27/2022
Neurocrine Biosciences, Inc. today announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia.